Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  head and neck cancer
Stage/Subtype:  head and neck cancer
Trial Type:  Treatment
Results 1-25 of 178 for your search:
Start Over
Radiation Therapy with Cisplatin, Docetaxel, or Cetuximab and Docetaxel after Surgery in Treating Patients with High-Risk Stage III-IV Squamous Cell Head and Neck Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1216, NCI-2013-00500, NCT01810913
Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients with Stage III-IV Oropharyngeal Cancer
Phase: Phase III, Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0825, NCI-2013-01879, NCT01893307
Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NRG-HN001, NCI-2014-00635, NCT02179164, RTOG-1305, NCT02135042
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
Phase: Phase III
Type: Treatment
Age: 18 to 72
Trial IDs: CS001P3, NCI-2014-01668, 2010-019952-35, NCT01265849
LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 1200.131, NCI-2012-02044, 2011-000392-14, NCT01345669
Radiation Therapy with or without Cisplatin in Treating Patients with Oropharyngeal Cancer Previously Treated with Surgery
Phase: Phase III
Type: Treatment
Age: 21 and over
Trial IDs: 201207059, NCI-2012-01230, NCT01687413
Study Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D1532C00065, NCI-2013-01983, EudraCT 2013-000423-14, NCT01843062
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CA209-141, NCI-2014-01268, 2013-003622-86, NCT02105636
Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-040, NCI-2014-02662, 2014-001749-26, NCT02252042
A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 3475-048, NCI-2015-00270, 2014-003698-41, NCT02358031
Intensity-Modulated Radiation Therapy, Pemetrexed Disodium, and Erlotinib Hydrochloride in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CCCWFU 60107, NCI-2009-01250, CCCWFU-IRB00003457, CDR0000578838, LILLY-CCCWFU-60107, NCT01580449, P30CA012197, NCT00573989
Caphosol for the Reduction of Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 603EUSA03, NCI-2010-01741, NCT00901732
Cetuximab, EGFR Antisense DNA, and Radiation Therapy in Treating Patients With Stage III-IV Squamous Cell Cancer of the Head and Neck
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 06-121, NCI-2013-00329, NCT00903461
Vitamin D - Celecoxib Therapy
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 85
Trial IDs: CLIN-003-09S, NCI-2015-00330, NCT00953849
Crolibulin and Cisplatin in Treating Patients with Recurrent or Metastatic Solid Tumors That Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 90
Trial IDs: 11-C-0027, NCI-2013-01471, 110027, 343865, P10677, NCT01240590
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: BBI608-201, NCI-2014-01566, NCT01325441
Cetuximab and Recombinant Interleukin-12 in Treating Patients with Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: OSU 11010, NCI-2011-03631, 11010, CDR0000715306, 8860, 2011C0019, NCT01468896
A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CBYL719X2104, NCI-2013-00766, 2011-006017-34, NCT01602315
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-1972, NCI-2013-00586, NCT01816984
Palbociclib and Cetuximab in Treating Patients with Squamous Cell Carcinoma of the Head and Neck
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 201404139, NCI-2014-01079, 14-X031, NCT02101034
A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D4981C00001, NCI-2014-01959, NCT02205333
Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CINC280X2104, NCI-2014-02359, 2014-000579-20, NCT02205398
Start Over